Plaquenil Dosage
Medically reviewed by A Ras MD.
Recommended Adult Dosing
Dosage forms: TAB: 200 mg
Malaria prophylaxis
- [400 mg PO qwk]
- Start: 1-2wk before exposure; Info: give w/ food or milk; do not cut/crush/chew tab; D/C 4wk after exposure; see CDC Pre-Travel Malaria Prophylaxis recommendations in Guidelines > Specialties > Infectious Diseases
Malaria tx
- [800 mg PO x1, then 400 mg PO x1 at 6h, 24h, and 48h]
- Info: give w/ food or milk; do not cut/crush/chew tab; to avoid relapse in acute P. vivax or P. ovale infection, follow up tx w/ primaquine or tafenoquine; refer to CDC guidelines
SLE
- [200 mg PO qd or 400 mg/day PO divided qd-bid]
- Info: give w/ food or milk; do not cut/crush/chew tab
Rheumatoid arthritis
- [200 mg PO qd or 400 mg/day PO divided qd-bid]
- Start: 400-600 mg/day PO divided qd-bid x4-12wk; Info: give w/ food or milk; do not cut/crush/chew tab
COVID-19
- [EUA revoked in US]
- Info: revoked June 15, 2020; no evidence of benefit for mortality or other outcomes and ongoing reports of serious cardiac adverse events; search ‘COVID’ for additional resources including guidelines, published study summaries, and clinical trial updates
Renal dosing
- renal impairment: consider decr. usual dose
- HD/PD: not defined
Hepatic dosing
- hepatic impairment: consider decr. usual dose
Recommended Peds Dosing
- Dosage forms: TAB: 200 mg
Malaria prophylaxis
- [infants/children, >31 kg]
- Dose: 6.5 mg/kg/dose PO qwk; Start: 1-2wk before exposure; Max: 400 mg/dose; Info: give w/ food or milk; do not cut/crush/chew tab; D/C 4wk after exposure; see CDC Pre-Travel Malaria Prophylaxis recommendations in Guidelines > Specialties > Infectious Diseases
Malaria tx
- [infants/children, >31 kg]
- Dose: 13 mg/kg/dose PO x1, then 6.5 mg/kg/dose PO x1 at 6h, 24h, and 48h; Max: 800 mg for initial dose, 400 mg for subsequent doses; Info: give w/ food or milk; do not cut/crush/chew tab; to avoid relapse in acute P. vivax or P. ovale infection, follow up tx w/ primaquine or tafenoquine; refer to CDC guidelines
COVID-19
- [EUA revoked in US]
- Info: revoked June 15, 2020; no evidence of benefit for mortality or other outcomes and ongoing reports of serious cardiac adverse events; search ‘COVID’ for additional resources including guidelines, published study summaries, and clinical trial updates
Renal dosing
- renal impairment: consider decr. usual dose
- HD/PD: not defined
Hepatic dosing
- hepatic impairment: consider decr. usual dose
SRC: NLM .